CencoraAs advanced therapeutic medicinal products (ATMPs) and other next-generation biologics move toward approval, Chemistry, Manufacturing and Controls (CMC) continues to be the most frequent source of regulatory concern. This article highlights recurring CMC barriers and best practices to mitigate approval delays or refusals.
Unsplash+Membrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s bispecific antibody platform for hard-to-treat targets.
AnaveonSwiss biotech company Anaveon has appointed a new Chief Executive Officer. As the company announced in March, experienced biopharma executive Thaminda Ramanayake will take over the leadership of the Basel-based firm.
adobe stock photos - Michael Derrer Fuchs Novartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD 3 billion.
Boehmert & BoehmertThe Unified Patent Court and the unitary patent were established to make patent litigation in Europe easier, faster and more affordable. It has been particularly emphasized that the new system was designed to enable small and medium-sized enterprises to enforce their rights more effectively and rapidly. The reality now suggests differently. Litigation in Europe has become quite fragmented, more complex and more expensive than ever – a nice playground for deep pockets.
The AI Circular Economy Conference 2026, organised by nova-Institute, brought together 116 participants from 15 countries in Cologne and online to explore the transformation of the chemical and materials industry supported and accelerated by artificial intelligence.
Featuring 100 exhibitors, keynote and podium speakers, behind-the-scenes access to a leading biotech campus, and a rich networking program, SLAS Europe 2026 is designed for professionals at every stage of their careers.
GeminiBiotech is entering its automated era. Robots run assays, AI designs molecules, and data drives decisions. For young scientists, the question is not survival, it is leadership. Will you adapt to the new lab, or help define it?
freepik.com / natalialbaAustria’s biotech sector is gaining momentum as the EU Biotech Act opens new opportunities. BIOTECH AUSTRIA and EuropaBio join forces to strengthen innovation, competitiveness, and Europe’s role as a global biotech leader.
Discover ELRIG’s quarter two events – three focused scientific meetings showcasing the newest technologies, models, and strategies redefining drug discovery. Join global experts advancing complex cellular systems, automation, and innovative target screening.